Smoking and Tobacco Control Monograph No. 7 
with a completely different method and what we think is a more precise 
method. 
DR. WOOSLEY: 1 think the point you make is that the predictive accuracy of 
any yield numbers, except at the low end of the scale, is useless, and 1 think 
that is the most important message that 1 got out of your presentation. 
The other message 1 have gotten out of the presentation was that this 
indicates that the differences in mortality that we saw earlier, which had the 
potential to be confounded, are very likely to be confounded because of the 
lack of a difference in exposure that your data indicate. 
DR. BENOWITZ: 1 would certainly agree with that. On the coronary heart 
disease data, for example, with the low-yield cigarettes, I think you can 
virtually assume that their exposure to everything was substantially the same. 
It is no surprise that there is no protective effect of smoking low-yield 
cigarettes for heart disease. 
DR. RICKERT: How relevant do you feel the absorption of nicotine is to the I 
levels of other harmful constituents, such as benzo(a)pyrene and biphenyl, 
which are probably more related to disease processes than nicotine per se? 
DR. BENOWITZ; I think there is considerable variability, and one has to look i 
at that issue. I don't think there are enough data to know for the range of ! 
products. I 
REFERENCES 
Benowitz, N.L. Pharmacologic aspects of cigarette 
smoking and nicotine addiction. New England 
Journal of Medicine 319: 1318-1330, 1988. 
Benowitz, N.L. Dosimetric studies of compensatory 
cigarette smoking. In: Independent Scientific 
Committee on Smoking and Health: Nicotine, Smoking, 
and the Low Tar Programme, London, November 18- 
20, 1986, N. Wald and P. Froggatt (Editors). Oxford: 
Oxford University Press, 1989, pp. 133-150. 
Benowitz, N.L., Hall, S.H., Herning, R.I., Jacob, P. Ill, 
Jones, R.T., Osman, A.-L. Smokers of low-yield 
cigarettes do not consume less nicotine. New 
England joumal of Medicine 309: 139-142, 1983b. 
Benowitz, N.L., Jacob, P. III. Daily intake of nicotine 
during cigarette smoking. Clinical Pharmacology and 
Therapeutics 35: 499-504, 1984a. 
Benowitz, N.L., Jacob, P. III. Nicotine and carbon 
monoxide intake from high- and low-yield 
cigarettes. Clinical Pharmacology and Therapeutics 
36: 265-270, 1984b. 
Benowitz, N.L., Jacob, P. 111. Nicotine renal excretion 
rate influences nicotine intake during cigarette 
smoking. Journal of Pharmacology and Exjierimental 
Therapeutics 234: 153-155, 1985. 
Benowitz, N.L., Jacob, P. III. Metabolism of nicotine to 
cotinine studied by a dual stable isotope method. 
(Uinical PharmuLology and Theraj)eutics 56(5): 483- 
493, 1994. 
Benowitz, N.L., Jacob, P. Ill, Denaro, C., Jenkins, R. 
Stable isotope studies of nicotine kinetics and 
bioavailability. Clinical Pharmacology and 
Therapeutics 49: 270-277, 1991. 
Benowitz, N.L., Jacob, P. Ill, Fong, L, Gupta, S. | 
Nicotine metabolic profile in man: Comparison I 
of cigarette smoking and transdermal nicotine. 
Jourtjal of Pharmacology and Experimental i 
Therajreutics 268: 296-303, 1994. | 
Benowitz, N.L., Jacob, P. Ill, Kozlowski, L.T., Yu, L. j 
Influence of smoking fewer cigarettes on exposure I 
to tar, nicotine, and carbon monoxide. New j 
England Journal of Medicine 315: 1310-1313, 1986a. | 
Benowitz, N.L., Jacob, P. Ill, Yu, L., Falcott, R., Hall, | 
S., Jones, R.'F. Reduced tar, nicotine, and carbon j 
monoxide exposure while smoking ultralow- but ji 
not low-yield cigarettes. Journal of the American 
Medical Association 2S6: 241-246, 1986b. 
Benowitz, N.L., Kuyt, F., Jacob, P. Ill, Jones, R.'F., > 
Osman, A.-L. Cotinine disposition and effects. 
Clinical Pharmacology and Therajreutics 34: 604-61 1, 
198.3a. I 
Byrd, G.D., Robinson, J. 11., (Caldwell, W.S., | 
DeBethizy, J.D. (lomparison of measured and | 
FTC-predicted nicotine uptake in smokers. 
Psychopharmacology \22: 9S-U)3, 1995. 
no 
